{"title":"脱碘酶III型多态性(Rs190716)对左旋甲状腺素治疗反应的影响","authors":"A. H. Mohmmed, Suzanne Jubair, B. Khalaf","doi":"10.4274/tjps.galenos.2022.04876","DOIUrl":null,"url":null,"abstract":"Objectives : Levothyroxine (LT4) is the commonly used treatment for hypothyroidism. Deiodinases enzymes control the metabolism and homeostasis of thyroid hormones (THs). Deiodinases type III (DIO3) gene encodes deiodinase type 3 enzyme (D3), the genetic polymorphisms of this gene could affect the levels of THs and then the response to LT4 treatment. This study aims to investigate the single nucleotide polymorphism (SNP), rs1190716; C>T, of DIO3 as a candidate genetic variant that might affect the clinical response to LT4 treatment. Materials and Methods: Two hundred Iraqi hypothyroid female patients who were aged 40 years or older were enrolled in this cross-sectional study. All of them were already on the LT4 treatment for at least 4 months. Thyroid hormones (thyroxin (T4), triiodothyrionine (T3), revers riiodothyrionine (rT3) and diiodothyrionine (T2)) were estimated. Allele specific-polymerase chain reaction technique was performed to detect the rs1190716; C>T SNP. Results: The genotypes distribution of rs1190716; C>T SNP was 10 (4.5%) for the wild type (CC), 50 (22.7%) for the heterozygous mutant type (TC), and 160 (72.7%) for the homozygous mutant type (TT). The patients were divided into three groups according to their genotypes. Significant differences were found in the levels of T4, T3 and T2 among the groups of the patients (P=0.019, P=0.039, P= 0.032, respectively) Conclusion: The rs1190716; C>T SNP could affect the activity of the D3 enzyme and the metabolic homeostasis of the THs, therefore rs1190716; C>T SNP could have an impact in the therapeutic response to LT4 in Iraqi female patients with primary hypothyroidism. Regarding the DIO3 gene, this is a novel finding, hence further studies are needed to conform it.","PeriodicalId":23378,"journal":{"name":"Turkish Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deiodinase Type III Polymorphism (Rs1190716) Affects The Therapeutic Response to Levothyroxine Short Title: Deiodinase Type III Gene and Hypothyroidism\",\"authors\":\"A. H. Mohmmed, Suzanne Jubair, B. Khalaf\",\"doi\":\"10.4274/tjps.galenos.2022.04876\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives : Levothyroxine (LT4) is the commonly used treatment for hypothyroidism. Deiodinases enzymes control the metabolism and homeostasis of thyroid hormones (THs). Deiodinases type III (DIO3) gene encodes deiodinase type 3 enzyme (D3), the genetic polymorphisms of this gene could affect the levels of THs and then the response to LT4 treatment. This study aims to investigate the single nucleotide polymorphism (SNP), rs1190716; C>T, of DIO3 as a candidate genetic variant that might affect the clinical response to LT4 treatment. Materials and Methods: Two hundred Iraqi hypothyroid female patients who were aged 40 years or older were enrolled in this cross-sectional study. All of them were already on the LT4 treatment for at least 4 months. Thyroid hormones (thyroxin (T4), triiodothyrionine (T3), revers riiodothyrionine (rT3) and diiodothyrionine (T2)) were estimated. Allele specific-polymerase chain reaction technique was performed to detect the rs1190716; C>T SNP. Results: The genotypes distribution of rs1190716; C>T SNP was 10 (4.5%) for the wild type (CC), 50 (22.7%) for the heterozygous mutant type (TC), and 160 (72.7%) for the homozygous mutant type (TT). The patients were divided into three groups according to their genotypes. Significant differences were found in the levels of T4, T3 and T2 among the groups of the patients (P=0.019, P=0.039, P= 0.032, respectively) Conclusion: The rs1190716; C>T SNP could affect the activity of the D3 enzyme and the metabolic homeostasis of the THs, therefore rs1190716; C>T SNP could have an impact in the therapeutic response to LT4 in Iraqi female patients with primary hypothyroidism. Regarding the DIO3 gene, this is a novel finding, hence further studies are needed to conform it.\",\"PeriodicalId\":23378,\"journal\":{\"name\":\"Turkish Journal of Pharmaceutical Sciences\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-12-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Pharmaceutical Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4274/tjps.galenos.2022.04876\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/tjps.galenos.2022.04876","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
目的:左旋甲状腺素(LT4)是甲状腺功能减退症的常用治疗方法。脱碘酶控制甲状腺激素(THs)的代谢和稳态。脱碘酶III型(DIO3)基因编码脱碘酶3型(D3),该基因的遗传多态性可能影响THs水平,进而影响对LT4治疗的反应。本研究旨在研究单核苷酸多态性(SNP)rs1190716;C> DIO3的T作为可能影响对LT4治疗的临床反应的候选基因变体。材料和方法:200名年龄在40岁或以上的伊拉克甲状腺功能减退症女性患者被纳入这项横断面研究。所有患者均已接受LT4治疗至少4个月。甲状腺激素(甲状腺素(T4)、三碘甲状腺激素(T3)、反三碘甲状腺素(rT3)和二碘甲状腺激素。应用等位基因特异性聚合酶链反应技术检测rs1190716;C> T SNP。结果:rs1190716的基因型分布;C> 野生型(CC)的T SNP为10(4.5%),杂合突变型(TC)为50(22.7%),纯合子突变型(TT)为160(72.7%)。根据基因型将患者分为三组。T4、T3和T2水平在各组间存在显著差异(分别为P=0.019、P=0.039、P=0.032)。结论:rs1190716;C> T SNP可以影响D3酶的活性和THs的代谢稳态,因此rs1190716;C> T SNP可能对原发性甲状腺功能减退的伊拉克女性患者对LT4的治疗反应产生影响。关于DIO3基因,这是一个新的发现,因此需要进一步的研究来证实它。
Deiodinase Type III Polymorphism (Rs1190716) Affects The Therapeutic Response to Levothyroxine Short Title: Deiodinase Type III Gene and Hypothyroidism
Objectives : Levothyroxine (LT4) is the commonly used treatment for hypothyroidism. Deiodinases enzymes control the metabolism and homeostasis of thyroid hormones (THs). Deiodinases type III (DIO3) gene encodes deiodinase type 3 enzyme (D3), the genetic polymorphisms of this gene could affect the levels of THs and then the response to LT4 treatment. This study aims to investigate the single nucleotide polymorphism (SNP), rs1190716; C>T, of DIO3 as a candidate genetic variant that might affect the clinical response to LT4 treatment. Materials and Methods: Two hundred Iraqi hypothyroid female patients who were aged 40 years or older were enrolled in this cross-sectional study. All of them were already on the LT4 treatment for at least 4 months. Thyroid hormones (thyroxin (T4), triiodothyrionine (T3), revers riiodothyrionine (rT3) and diiodothyrionine (T2)) were estimated. Allele specific-polymerase chain reaction technique was performed to detect the rs1190716; C>T SNP. Results: The genotypes distribution of rs1190716; C>T SNP was 10 (4.5%) for the wild type (CC), 50 (22.7%) for the heterozygous mutant type (TC), and 160 (72.7%) for the homozygous mutant type (TT). The patients were divided into three groups according to their genotypes. Significant differences were found in the levels of T4, T3 and T2 among the groups of the patients (P=0.019, P=0.039, P= 0.032, respectively) Conclusion: The rs1190716; C>T SNP could affect the activity of the D3 enzyme and the metabolic homeostasis of the THs, therefore rs1190716; C>T SNP could have an impact in the therapeutic response to LT4 in Iraqi female patients with primary hypothyroidism. Regarding the DIO3 gene, this is a novel finding, hence further studies are needed to conform it.